<!DOCTYPE html>
<!-- Generated by pkgdown: do not edit by hand --><html lang="en">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Available visualisations and tables • TB in England Data Clean</title>
<!-- jquery --><script src="https://cdnjs.cloudflare.com/ajax/libs/jquery/3.3.1/jquery.min.js" integrity="sha256-FgpCb/KJQlLNfOu91ta32o/NMZxltwRo8QtmkMRdAu8=" crossorigin="anonymous"></script><!-- Bootstrap --><link href="https://cdnjs.cloudflare.com/ajax/libs/bootswatch/3.3.7/lumen/bootstrap.min.css" rel="stylesheet" crossorigin="anonymous">
<script src="https://cdnjs.cloudflare.com/ajax/libs/twitter-bootstrap/3.3.7/js/bootstrap.min.js" integrity="sha256-U5ZEeKfGNOja007MMD3YBI0A3OSZOQbeG6z2f2Y0hu8=" crossorigin="anonymous"></script><!-- Font Awesome icons --><link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.7.1/css/all.min.css" integrity="sha256-nAmazAk6vS34Xqo0BSrTb+abbtFlgsFK7NKSi6o7Y78=" crossorigin="anonymous">
<link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.7.1/css/v4-shims.min.css" integrity="sha256-6qHlizsOWFskGlwVOKuns+D1nB6ssZrHQrNj1wGplHc=" crossorigin="anonymous">
<!-- clipboard.js --><script src="https://cdnjs.cloudflare.com/ajax/libs/clipboard.js/2.0.4/clipboard.min.js" integrity="sha256-FiZwavyI2V6+EXO1U+xzLG3IKldpiTFf3153ea9zikQ=" crossorigin="anonymous"></script><!-- headroom.js --><script src="https://cdnjs.cloudflare.com/ajax/libs/headroom/0.9.4/headroom.min.js" integrity="sha256-DJFC1kqIhelURkuza0AvYal5RxMtpzLjFhsnVIeuk+U=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/headroom/0.9.4/jQuery.headroom.min.js" integrity="sha256-ZX/yNShbjqsohH1k95liqY9Gd8uOiE1S4vZc+9KQ1K4=" crossorigin="anonymous"></script><!-- pkgdown --><link href="../pkgdown.css" rel="stylesheet">
<script src="../pkgdown.js"></script><meta property="og:title" content="Available visualisations and tables">
<meta property="og:description" content="">
<meta name="twitter:card" content="summary">
<!-- mathjax --><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/MathJax.js" integrity="sha256-nvJJv9wWKEm88qvoQl9ekL2J+k/RWIsaSScxxlsrv8k=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/config/TeX-AMS-MML_HTMLorMML.js" integrity="sha256-84DKXVJXs0/F8OTMzX4UR909+jtl4G7SPypPavF+GfA=" crossorigin="anonymous"></script><!--[if lt IE 9]>
<script src="https://oss.maxcdn.com/html5shiv/3.7.3/html5shiv.min.js"></script>
<script src="https://oss.maxcdn.com/respond/1.4.2/respond.min.js"></script>
<![endif]-->
</head>
<body>
    <div class="container template-article">
      <header><div class="navbar navbar-inverse navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-target="#navbar" aria-expanded="false">
        <span class="sr-only">Toggle navigation</span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <span class="navbar-brand">
        <a class="navbar-link" href="../index.html">TB in England Data Clean</a>
        <span class="version label label-default" data-toggle="tooltip" data-placement="bottom" title="Released version">1.0.0</span>
      </span>
    </div>

    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
<li>
  <a href="../index.html">Home</a>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" aria-expanded="false">
    Vignettes
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
<li>
      <a href="../articles/make_data.html">Use the package to construct the data</a>
    </li>
    <li>
      <a href="../articles/pop_changes_life_expect.html">Estimating UK born mortality and emmigration rates</a>
    </li>
    <li>
      <a href="../articles/visualisations_and_tables.html">Available visualisations and tables</a>
    </li>
  </ul>
</li>
      </ul>
<ul class="nav navbar-nav navbar-right">
<li>
  <a href="../reference/index.html">
    <span class="fa fa-file-code-o"></span>
     
    Functions
  </a>
</li>
<li>
  <a href="https://github.com/seabbs/tbinenglanddataclean/">
    <span class="fa fa-github fa-lg"></span>
     
    Github
  </a>
</li>
      </ul>
</div>
<!--/.nav-collapse -->
  </div>
<!--/.container -->
</div>
<!--/.navbar -->

      
      </header><script src="visualisations_and_tables_files/kePrint-0.0.1/kePrint.js"></script><div class="row">
  <div class="col-md-9 contents">
    <div class="page-header toc-ignore">
      <h1>Available visualisations and tables</h1>
                        <h4 class="author">Sam Abbott</h4>
            
            <h4 class="date">2019-07-11</h4>
      
      <small class="dont-index">Source: <a href="https://github.com/seabbs/tbinenglanddataclean/blob/master/vignettes/visualisations_and_tables.Rmd"><code>vignettes/visualisations_and_tables.Rmd</code></a></small>
      <div class="hidden name"><code>visualisations_and_tables.Rmd</code></div>

    </div>

    
    
<div id="required-packages" class="section level2">
<h2 class="hasAnchor">
<a href="#required-packages" class="anchor"></a>Required Packages</h2>
<div class="sourceCode" id="cb1"><pre class="sourceCode r"><code class="sourceCode r"><a class="sourceLine" id="cb1-1" data-line-number="1"><span class="kw"><a href="https://rdrr.io/r/base/library.html">library</a></span>(tbinenglanddataclean)</a></code></pre></div>
<pre><code>## Registered S3 methods overwritten by 'ggplot2':
##   method         from 
##   [.quosures     rlang
##   c.quosures     rlang
##   print.quosures rlang</code></pre>
<div class="sourceCode" id="cb3"><pre class="sourceCode r"><code class="sourceCode r"><a class="sourceLine" id="cb3-1" data-line-number="1"><span class="kw"><a href="https://rdrr.io/r/base/library.html">library</a></span>(kableExtra)</a>
<a class="sourceLine" id="cb3-2" data-line-number="2"><span class="kw"><a href="https://rdrr.io/r/base/library.html">library</a></span>(rlang)</a>
<a class="sourceLine" id="cb3-3" data-line-number="3"><span class="kw"><a href="https://rdrr.io/r/base/library.html">library</a></span>(ggplot2)</a></code></pre></div>
<div id="tb-interventions" class="section level3">
<h3 class="hasAnchor">
<a href="#tb-interventions" class="anchor"></a>TB Interventions</h3>
<table class="table table table">
<caption style="font-size: initial !important;">
A timeline of interventions against TB. Antibiotics used to treat TB are commonly given together, with those with the fewest side effects given first. Second line antibiotics are then used if the initial treatment fails or tests show the strain is multiply drug resistant. BCG - Bacillus Calmette–Guérin; TB – Tuberculosis; MRSA - Methicillin-resistant Staphylococcus aureus; DOTS - Directly Observed Treatment Short-course
</caption>
<thead><tr>
<th style="text-align:right;">
Year
</th>
<th style="text-align:left;">
Intervention
</th>
<th style="text-align:left;">
Type
</th>
<th style="text-align:left;">
Line
</th>
<th style="text-align:left;">
Detail
</th>
</tr></thead>
<tbody>
<tr>
<td style="text-align:right;">
1921
</td>
<td style="text-align:left;">
BCG
</td>
<td style="text-align:left;">
Vaccination
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;width: 10cm; ">
The first use of the Bacillus Calmette–Guerin (BCG) vaccine in humans, it remains the only vaccine against Tuberculosis (TB). Efficacy has been shown to vary depending on latitude and there is only strong evidence of protection for 10-15 years after vaccination.
</td>
</tr>
<tr>
<td style="text-align:right;">
1944
</td>
<td style="text-align:left;">
Streptomycin
</td>
<td style="text-align:left;">
Antibiotic
</td>
<td style="text-align:left;">
Second
</td>
<td style="text-align:left;width: 10cm; ">
The first antibiotic and the first bacterial agent against TB.
</td>
</tr>
<tr>
<td style="text-align:right;">
1944
</td>
<td style="text-align:left;">
4-Aminosalicylic acid
</td>
<td style="text-align:left;">
Antibiotic
</td>
<td style="text-align:left;">
Second
</td>
<td style="text-align:left;width: 10cm; ">
The second antiobiotic to be developed. Due to lower potency than other antibiotics it is not considered a first line treatment.
</td>
</tr>
<tr>
<td style="text-align:right;">
1952
</td>
<td style="text-align:left;">
Isoniazid
</td>
<td style="text-align:left;">
Antibiotic
</td>
<td style="text-align:left;">
First
</td>
<td style="text-align:left;width: 10cm; ">
Used against both active and latent TB, it may also be given as a prophylatic therapy.
</td>
</tr>
<tr>
<td style="text-align:right;">
1952
</td>
<td style="text-align:left;">
Cycloserine
</td>
<td style="text-align:left;">
Antibiotic
</td>
<td style="text-align:left;">
Second
</td>
<td style="text-align:left;width: 10cm; ">
An antibiotic with severe side effects such as kidney failure and neurological conditions, which is therefore restricted for use against multiple drug resistant TB.
</td>
</tr>
<tr>
<td style="text-align:right;">
1952
</td>
<td style="text-align:left;">
Pyrazinamide
</td>
<td style="text-align:left;">
Antibiotic
</td>
<td style="text-align:left;">
First
</td>
<td style="text-align:left;width: 10cm; ">
Discovered in 1936, it was first used against TB in 1952. Although showing no effect in-vitro it was shown to be effective in treating TB in mice. Used only for treating TB and never on its own.
</td>
</tr>
<tr>
<td style="text-align:right;">
1953
</td>
<td style="text-align:left;">
School age BCG
</td>
<td style="text-align:left;">
Vaccination
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;width: 10cm; ">
After a successful trial which showed high effectiveness for the vaccine, BCG was introduced in the UK for those at school leaving age as peak incidence was then in young, working adults.
</td>
</tr>
<tr>
<td style="text-align:right;">
1962
</td>
<td style="text-align:left;">
Ethambutol
</td>
<td style="text-align:left;">
Antibiotic
</td>
<td style="text-align:left;">
First
</td>
<td style="text-align:left;width: 10cm; ">
Believed to work by interfering with TB bacteria’s metabolism. There are some concerns that it may not be safe to give during pregancy, as it may lead to vision loss in the baby.
</td>
</tr>
<tr>
<td style="text-align:right;">
1971
</td>
<td style="text-align:left;">
Rifampicin
</td>
<td style="text-align:left;">
Antibiotic
</td>
<td style="text-align:left;">
First
</td>
<td style="text-align:left;width: 10cm; ">
Taken daily for at least a period of 6 months, if given alone resistance develops quickly. It may also be used in the treatment of MRSA amongst other diseases.
</td>
</tr>
<tr>
<td style="text-align:right;">
1995
</td>
<td style="text-align:left;">
DOTS
</td>
<td style="text-align:left;">
Strategy
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;width: 10cm; ">
Directly Observed Treatment, Short-Course (DOTS) is introdued by the World Health Organization as a control strategy for TB. The intermittent, supervised system aims to eliminate drug default.
</td>
</tr>
<tr>
<td style="text-align:right;">
2005
</td>
<td style="text-align:left;">
Neonatal high risk BCG
</td>
<td style="text-align:left;">
Vaccination
</td>
<td style="text-align:left;">
</td>
<td style="text-align:left;width: 10cm; ">
Due to a continued decline in TB incidence rates in the indigenous UK population, the BCG programme was refocused as risk-based. This meant vaccinating high risk neonates rather than those most likely to transmit TB.
</td>
</tr>
<tr>
<td style="text-align:right;">
2012
</td>
<td style="text-align:left;">
Bedaquiline
</td>
<td style="text-align:left;">
Antibiotic
</td>
<td style="text-align:left;">
Second
</td>
<td style="text-align:left;width: 10cm; ">
The first new antiobiotic for use against TB in 40 years, reserved for use against multiple drug resistant TB. Approved via a fast track process, higher mortality in those that recieve the antibiotic has caused significant concern.
</td>
</tr>
</tbody>
</table>
<div id="tb-notifications" class="section level4">
<h4 class="hasAnchor">
<a href="#tb-notifications" class="anchor"></a>TB Notifications</h4>
<div class="figure">
<img src="visualisations_and_tables_files/figure-html/plot-incidence-1.png" alt="TB notifications in England and Wales from 1913 to 2017, stratified initially by respiratory/non-respiratory status and from 1982 by pulmonary/non-pulmonary TB. Interventions are highlighted with vertical lines, with linetype denoting the type of intervention, more information on each intervention is available in the corresponding table. Figure produced using tbinenglanddataclean (https://www.samabbott.co.uk/tbinenglanddataclean/)" width="3000"><p class="caption">
TB notifications in England and Wales from 1913 to 2017, stratified initially by respiratory/non-respiratory status and from 1982 by pulmonary/non-pulmonary TB. Interventions are highlighted with vertical lines, with linetype denoting the type of intervention, more information on each intervention is available in the corresponding table. Figure produced using tbinenglanddataclean (<a href="https://www.samabbott.co.uk/tbinenglanddataclean/" class="uri">https://www.samabbott.co.uk/tbinenglanddataclean/</a>)
</p>
</div>
</div>
<div id="pulmonary-vs--extra-pulmonary-tb" class="section level4">
<h4 class="hasAnchor">
<a href="#pulmonary-vs--extra-pulmonary-tb" class="anchor"></a>Pulmonary Vs. Extra-Pulmonary TB</h4>
<div class="figure">
<img src="visualisations_and_tables_files/figure-html/plot-prop-pul-1.png" alt="From 1913 until 1981 the figure shows the proportion respiratory vs. non-respiratory cases and from 1982 it shows the proportion of pulmonary vs. non-pulmonary TB. Figure produced using tbinenglanddataclean (https://www.samabbott.co.uk/tbinenglanddataclean/)" width="3000"><p class="caption">
From 1913 until 1981 the figure shows the proportion respiratory vs. non-respiratory cases and from 1982 it shows the proportion of pulmonary vs. non-pulmonary TB. Figure produced using tbinenglanddataclean (<a href="https://www.samabbott.co.uk/tbinenglanddataclean/" class="uri">https://www.samabbott.co.uk/tbinenglanddataclean/</a>)
</p>
</div>
</div>
</div>
</div>
  </div>

  <div class="col-md-3 hidden-xs hidden-sm" id="sidebar">
        <div id="tocnav">
      <h2 class="hasAnchor">
<a href="#tocnav" class="anchor"></a>Contents</h2>
      <ul class="nav nav-pills nav-stacked">
<li><a href="#required-packages">Required Packages</a></li>
      </ul>
</div>
      </div>

</div>


      <footer><div class="copyright">
  <p>Developed by Sam Abbott.</p>
</div>

<div class="pkgdown">
  <p>Site built with <a href="https://pkgdown.r-lib.org/">pkgdown</a> 1.3.0.9100.</p>
</div>
      </footer>
</div>

  

  </body>
</html>
